

1.3.2. WT2 list of deliverables

Deliverable Number ¹⁴	Deliverable Title	WP number ⁹	Lead beneficiary	Type ¹⁵	Dissemination level ¹⁶	Due Date (in months) ¹⁷
D1.1	Multi Stake-holder Research Agenda	WP1	2 - IRD	Report	Public	10
D1.2	Governance Standard Operating Procedures (SOP)	WP1	12 - SP	Report	Public	3
D1.3	Final report on governance and principles	WP1	12 - SP	Report	Public	60
D1.4	Generic post authorisation development plan on effectiveness of vaccines	WP1	2 - IRD	Report	Public	60
D1.5	Report on the Governance SOP implementation	WP1	2 - IRD	Report	Public	22
D2.1	Standard Operating Procedures (SOPs) and templates	WP2	8 - SURREY	Report	Public	8
D2.2	Report of the results of a systematic analysis on existing initiatives, tools, and/or study protocols for determining IVE [...]	WP2	15 - GSK Bio	Report	Public	12
D2.3	Electronic study support application	WP2	3 - P95	Websites, patents filling, etc.	Public	12
D2.4	Guideline for the identification of vaccine status and vaccine used in study participants	WP2	15 - GSK Bio	Report	Public	16
D2.5	Annual tender for influenza vaccine effectiveness study conduct	WP2	1 - FISABIO	Report	Public	16
D2.6	Recommendations for virological analysis of samples of the studies	WP2	10 - UCBL	Report	Public	30
D3.1	Report on the sources for usage of specific influenza vaccine brands and accessibility	WP3	3 - P95	Report	Public	6

Deliverable Number¹⁴	Deliverable Title	WP number⁹	Lead beneficiary	Type¹⁵	Dissemination level¹⁶	Due Date (in months)¹⁷
D3.2	SWOT analysis plan and list of quality criteria	WP3	7 - ISS	Report	Public	8
D3.3	Report on the brand availability and usage of specific influenza vaccine brands	WP3	7 - ISS	Report	Public	12
D3.4	Report on the comparison of adapted local protocols and Ethical Committee evaluation in each study site	WP3	4 - UNIFI	Report	Public	12
D3.5	Written report on quality and feasibility evaluation	WP3	7 - ISS	Report	Public	14
D4.1	Methodology guidelines for concerted analysis of data and control of confounding factors	WP4	3 - P95	Report	Public	4
D4.2	Generic DMP	WP4	3 - P95	Report	Public	6
D4.3	Report templates	WP4	7 - ISS	Report	Public	8
D4.4	Generic SAP	WP4	3 - P95	Report	Public	9
D4.5	IT infrastructure to receive and analyse the data	WP4	3 - P95	Websites, patents filling, etc.	Public	12
D4.6	Points to consider document on the interpretation of VE results	WP4	1 - FISABIO	Report	Public	12
D4.7	Evaluation reports of how the vaccine effectiveness results could fulfil the new regulatory requirements	WP4	11 - IABS-EU	Report	Public	15
D4.8	Mid-Term DMP	WP4	3 - P95	Report	Public	30
D4.9	Final DMP	WP4	3 - P95	Report	Public	60
D5.1	Communication of a detailed stakeholder map for the DRIVE project	WP5	6 - THL	Report	Public	3
D5.2	Agreement on communications governance model	WP5	6 - THL	Report	Public	5

Deliverable Number¹⁴	Deliverable Title	WP number⁹	Lead beneficiary	Type¹⁵	Dissemination level¹⁶	Due Date (in months)¹⁷
D5.3	Web-based survey amongst layer 1 stakeholders	WP5	6 - THL	Report	Public	6
D5.4	Development of the communications plan	WP5	6 - THL	Report	Public	12
D5.5	Report on the collected feed-back from “layer 1” [...]	WP5	6 - THL	Report	Public	14
D5.6	Periodical back-to-back Forum of key stakeholders [...]	WP5	11 - IABS-EU	Report	Public	14
D5.7	Report on synergies identified and collaborations developed with other initiatives	WP5	2 - IRD	Report	Public	18
D5.8	Tailored, timely seasonal summaries of VE results for different stakeholder/clients in layer 1 and 2	WP5	6 - THL	Report	Public	10
D5.9	Communication report of the study milestones arising from WP7 for the use of “layer 1” stakeholders	WP5	6 - THL	Report	Public	20
D5.10	Report on knowledge gaps needing future R&D efforts in IVE studies	WP5	6 - THL	Report	Public	48
D6.1	Templates for monitoring the work progress aligned and distributed	WP6	12 - SP	Report	Confidential, only for members of the consortium (including the Commission Services)	3
D6.2	Report with the definition of the ethics policies handbooks collection	WP6	1 - FISABIO	Report	Public	5
D6.3	Project Handbook	WP6	5 - SYNAPSE	Report	Public	6
D6.4	Project assessment	WP6	12 - SP	Report	Public	28
D6.5	Final Report and Sustainability Plan	WP6	1 - FISABIO	Report	Public	60
D7.1	Updated and developed protocol for type- and brand- specific IVES	WP7	7 - ISS	Report	Public	3

Deliverable Number¹⁴	Deliverable Title	WP number⁹	Lead beneficiary	Type¹⁵	Dissemination level¹⁶	Due Date (in months)¹⁷
D7.2	Updated protocol for type- and brand-specific influenza vaccine effectiveness studies (population-based database studies)	WP7	6 - THL	Report	Public	3
D7.3	Report on feasible novel and innovative approaches for measuring influenza VE	WP7	3 - P95	Report	Public	12
D7.4	First seasonal final report of conducted studies	WP7	3 - P95	Report	Public	12
D7.5	Report on feasibility study for influenza virus characterization, molecular epidemiology studies related to influenza related disease in vaccinated and unvaccinated subjects	WP7	10 - UCBL	Report	Public	22
D7.6	Second seasonal final report of conducted studies	WP7	3 - P95	Report	Public	22
D7.7	Third seasonal final report of conducted studies	WP7	3 - P95	Report	Public	34
D7.8	Fourth seasonal final report of conducted studies	WP7	3 - P95	Report	Public	46
D7.9	Fifth seasonal final report of conducted studies	WP7	3 - P95	Report	Public	58
D8.1	HCT - Requirement No. 2	WP8	1 - FISABIO	Ethics	Confidential, only for members of the consortium (including the Commission Services)	12
D8.2	POPD - Requirement No. 3	WP8	1 - FISABIO	Ethics	Confidential, only for members of the consortium (including the Commission Services)	12
D8.3	POPD - Requirement No. 5	WP8	1 - FISABIO	Ethics	Confidential, only for members	12

Deliverable Number¹⁴	Deliverable Title	WP number⁹	Lead beneficiary	Type¹⁵	Dissemination level¹⁶	Due Date (in months)¹⁷
					of the consortium (including the Commission Services)	
D8.4	POPD - Requirement No. 6	WP8	1 - FISABIO	Ethics	Confidential, only for members of the consortium (including the Commission Services)	12